Literature DB >> 26340116

Up-front polytherapy for ALK-positive lung cancer.

Bingying Zhou1, Adrienne D Cox2.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26340116     DOI: 10.1038/nm.3942

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  9 in total

1.  Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

Authors:  Adam S Crystal; Alice T Shaw; Lecia V Sequist; Luc Friboulet; Matthew J Niederst; Elizabeth L Lockerman; Rosa L Frias; Justin F Gainor; Arnaud Amzallag; Patricia Greninger; Dana Lee; Anuj Kalsy; Maria Gomez-Caraballo; Leila Elamine; Emily Howe; Wooyoung Hur; Eugene Lifshits; Hayley E Robinson; Ryohei Katayama; Anthony C Faber; Mark M Awad; Sridhar Ramaswamy; Mari Mino-Kenudson; A John Iafrate; Cyril H Benes; Jeffrey A Engelman
Journal:  Science       Date:  2014-11-13       Impact factor: 47.728

2.  SnapShot: non-small cell lung cancer.

Authors:  Rebecca S Heist; Jeffrey A Engelman
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

Review 3.  Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.

Authors:  Ryohei Katayama; Christine M Lovly; Alice T Shaw
Journal:  Clin Cancer Res       Date:  2015-05-15       Impact factor: 12.531

4.  A functional landscape of resistance to ALK inhibition in lung cancer.

Authors:  Frederick H Wilson; Cory M Johannessen; Federica Piccioni; Pablo Tamayo; Jong Wook Kim; Eliezer M Van Allen; Steven M Corsello; Marzia Capelletti; Antonio Calles; Mohit Butaney; Tanaz Sharifnia; Stacey B Gabriel; Jill P Mesirov; William C Hahn; Jeffrey A Engelman; Matthew Meyerson; David E Root; Pasi A Jänne; Levi A Garraway
Journal:  Cancer Cell       Date:  2015-03-09       Impact factor: 31.743

Review 5.  Targeting RAS-ERK signalling in cancer: promises and challenges.

Authors:  Ahmed A Samatar; Poulikos I Poulikakos
Journal:  Nat Rev Drug Discov       Date:  2014-12       Impact factor: 84.694

Review 6.  Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Authors:  D Ross Camidge; William Pao; Lecia V Sequist
Journal:  Nat Rev Clin Oncol       Date:  2014-07-01       Impact factor: 66.675

7.  RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer.

Authors:  Gorjan Hrustanovic; Victor Olivas; Evangelos Pazarentzos; Asmin Tulpule; Saurabh Asthana; Collin M Blakely; Ross A Okimoto; Luping Lin; Dana S Neel; Amit Sabnis; Jennifer Flanagan; Elton Chan; Marileila Varella-Garcia; Dara L Aisner; Aria Vaishnavi; Sai-Hong I Ou; Eric A Collisson; Eiki Ichihara; Philip C Mack; Christine M Lovly; Niki Karachaliou; Rafael Rosell; Jonathan W Riess; Robert C Doebele; Trever G Bivona
Journal:  Nat Med       Date:  2015-08-24       Impact factor: 53.440

Review 8.  Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology.

Authors:  Bengt Hallberg; Ruth H Palmer
Journal:  Nat Rev Cancer       Date:  2013-10       Impact factor: 60.716

9.  Combined effect of ALK and MEK inhibitors in EML4-ALK-positive non-small-cell lung cancer cells.

Authors:  J Tanizaki; I Okamoto; K Takezawa; K Sakai; K Azuma; K Kuwata; H Yamaguchi; E Hatashita; K Nishio; P A Janne; K Nakagawa
Journal:  Br J Cancer       Date:  2012-01-12       Impact factor: 7.640

  9 in total
  3 in total

1.  Codrug Approach for the Potential Treatment of EML4-ALK Positive Lung Cancer.

Authors:  Aimie E Garces; Mohammed Al-Hayali; Jong Bong Lee; Jiaxin Li; Pavel Gershkovich; Tracey D Bradshaw; Michael J Stocks
Journal:  ACS Med Chem Lett       Date:  2019-09-27       Impact factor: 4.345

Review 2.  Methods for CRISPR-Cas as Ribonucleoprotein Complex Delivery In Vivo.

Authors:  Alesya G Bykonya; Alexander V Lavrov; Svetlana A Smirnikhina
Journal:  Mol Biotechnol       Date:  2022-03-24       Impact factor: 2.695

3.  Identification of LBX2 as a novel causal gene of lung adenocarcinoma.

Authors:  Jingwen Hu; Yongkang Bai; Quanli Zhang; Ming Li; Rong Yin; Lin Xu
Journal:  Thorac Cancer       Date:  2020-06-22       Impact factor: 3.500

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.